GILD NASDAQ
Gilead Sciences, Inc.
1W: -1.2%
1M: -1.8%
3M: -13.8%
YTD: +7.3%
1Y: +22.1%
3Y: +83.5%
5Y: +128.2%
$134.36
+3.86 (+2.96%)
Weekly Expected Move ±3.3%
$121
$125
$130
$134
$138
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.00
Neutral
2 bullish
1 neutral
2 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (100)
Gilead's Hepcludex wins FDA approval for chronic HDV infection
Assembly Biosciences prices $100M equity offering
Top Analyst Reports for Applied Materials, Shell & KLA
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law
Trump 'Most Favored Nation' drug policy risks China R&D takeover
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Most healthcare companies report higher Y/Y EPS in strong earnings week
Earnings Scoreboard: 82% of firms post Y/Y earnings growth, 88% of S&P 500 reporting firms top EPS estimates
Trump says unaware of a plan to fire FDA commissioner
Nasdaq Tops 29,000 Records, Micron Soars 13%: Stock Market Today
Trump to fire FDA commissioner Marty Makary: WSJ
GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View
Gilead (GILD) Q1 2026 Earnings Call Transcript
Gilead Sciences declares $0.82 dividend
Gilead targets $1B Yeztugo sales in 2026 while raising base business outlook to $29.4B-$29.8B
Gilead slips despite Q1 beats as it now expects 2026 loss per share
Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
Gilead Sciences Non-GAAP EPS of $2.03 beats by $0.12, revenue of $6.96B beats by $30M
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Gilead Sciences Q1 2026 Earnings Preview: Steady growth ahead?
Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Catalyst Watch: Jobs report, Disney drama, Citi event, and Mickey D's crafted beverage push
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Pharma stocks rebound on cheap valuations, patent cliff fears ease, UBS says—CNBC interview
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Gilead Sciences, Inc. $GILD Stock Holdings Lifted by D.A. Davidson & CO.
Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
3 Healthcare Stocks That Pay You While You Wait for the Growth
Vanguard Group Inc. Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Brindle & Bay Financial Advisors LLC Purchases Shares of 6,042 Gilead Sciences, Inc. $GILD
Axecap Investments LLC Has $3.43 Million Stock Holdings in Gilead Sciences, Inc. $GILD
AEGON ASSET MANAGEMENT UK Plc Reduces Holdings in Gilead Sciences, Inc. $GILD
Calamos Advisors LLC Sells 9,121 Shares of Gilead Sciences, Inc. $GILD
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
Atwood & Palmer Inc. Has $42.94 Million Holdings in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Shares Sold by Arizona State Retirement System
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
Breakfast News: IBM Hit by Inflation's Long Shadow
Caprock Group LLC Buys 12,895 Shares of Gilead Sciences, Inc. $GILD
B. Metzler seel. Sohn & Co. AG Acquires 17,584 Shares of Gilead Sciences, Inc. $GILD
What's Going On With Arcus Biosciences Stock On Wednesday?
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
Abbott is the most oversold healthcare stock as Q1 earnings roll on
Merck gains approval of HIV drug regimen Idvynso
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Earned Wealth Advisors LLC Increases Holdings in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Shares Acquired by AE Wealth Management LLC
Gilead Sciences, Inc. $GILD Position Raised by Asset Management One Co. Ltd.
Corporate America’s big job cuts in 2026 - What do we know so far?
Gilead extends Arcellx tender offer again
Farther Finance Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc.
Tempus AI Expands Strategic Partnership Amid Oncology Boom
Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
Altfest L J & Co. Inc. Sells 4,944 Shares of Gilead Sciences, Inc. $GILD
Key deals this week: Organon, UMG, Whitestone REIT, Gilead and more
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
Gilead projects $107M Q1 earnings headwind due to recent R&D deals
Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline
Gilead Expands Oncology Pipeline With $5B Tubulis Deal
SA analyst upgrades/downgrades: PLTR, RIVN, GILD, INTC
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
Gilead to acquire Tubulis GmbH for $5B
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Leo Wealth LLC Purchases 3,680 Shares of Gilead Sciences, Inc. $GILD
Perpetual Ltd Raises Position in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Position Reduced by Aberdeen Group plc
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $10.37 Million Stake in Gilead Sciences, Inc. $GILD
Banque Pictet & Cie SA Purchases 142,543 Shares of Gilead Sciences, Inc. $GILD
Bank Pictet & Cie Europe AG Purchases 136,605 Shares of Gilead Sciences, Inc. $GILD
Allspring Global Investments Holdings LLC Purchases 71,872 Shares of Gilead Sciences, Inc. $GILD
No deal yet? Trump readies 100% tariffs on select drugmakers - report
Lilly CEO says company opposes codification of Trump drug pricing deals
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
AI-linked stocks see surge in ownership breadth, led by Palantir and GE Vernova
Brookstone Capital Management Sells 5,279 Shares of Gilead Sciences, Inc. $GILD
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Is Trump to blame for delayed drug launches in Europe
Wall Street crowds into AI plays as ownership breadth jumps